Navigation Links
Cipher provides CIP-TRAMADOL ER regulatory update
Date:2/11/2008

Toronto Stock Exchange Symbol: DND

MISSISSAUGA, ON, Feb. 11 /PRNewswire-FirstCall/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced that the U.S. Food and Drug Administration (FDA) has suggested an additional statistical sensitivity analysis of existing clinical data on CIP-TRAMADOL ER, Cipher's extended-release tramadol formulation, as a means to potentially satisfy the requirements for approval.

In December 2007, Cipher appealed the decision in the Agency's May 2007 Approvable Letter through the Formal Dispute Resolution process. On February 1, 2008, the Company announced that it received a written response from the FDA regarding its first stage of appeal. In the response, the Acting Director of the Office of Drug Evaluation II, Center for Drug Evaluation and Research supported the Division's approvable action. In a subsequent discussion with Cipher, the Agency informed Cipher of the new analysis as an alternative to continuing the Formal Dispute Resolution process.

As a consequence, Cipher is suspending its appeal at this time and expects to meet with the Division in the near future to obtain further details on the additional analysis.

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals is a drug development company focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies. Cipher's strategy is to in-license products that incorporate proven drug delivery technologies and advance them through the clinical development and regulatory approval stages, after which the products are out-licensed to international partners. Because Cipher's products are based on proven technology platforms applied to currently marketed drugs, they are expected to have lower approval risk, shorter development timelines and significantly lower development costs. The Company's lead compound, CIP-FENOFIBRATE, received final approval from the U.S. Fo
'/>"/>

SOURCE Cipher Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cipher appoints Stefan Aigner to board of directors
2. Cipher Appeals FDAs Decision On CIP-TRAMADOL ER
3. Cipher reports third quarter fiscal 2007 results
4. Legal Employer Provides Companies with Competitive Edge by Assuring Consumers that Workers are Legally Documented
5. Laser Energetics Provides Joint Venture Update to Shareholders
6. ATS Medical Provides Update on First Generation Tissue Valve Approval
7. OxySure(R) Systems, Inc. Named to 2008 Worlds Best Technologies (WBT) List For its Unique, Safe and Easy to Use Portable Emergency Oxygen Generator, Which Provides Medical Oxygen Without the Need for Compressed Tanks
8. GfK Asia Provides New View on the Optics Industry
9. Young Innovations, Inc. Provides Fourth Quarter Conference Call Details
10. NutraCea Provides Update on Domestic Operations
11. Mylan Provides Update Relating to Ongoing Lorazepam and Clorazepate Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... ... September 04, 2015 , ... Inmar announced today that its ... its Product, Quality and Manufacturers, Dietary Supplements and Supply Chain Committees. , With ... consumer goods industry, it can be difficult for companies to navigate, stay abreast ...
(Date:9/4/2015)... ... , ... “Getting away from the daily stressors and distractions of life may ... ‘couple-ness,’” says Jean Claude Wietzel, general manager at Four Seasons Resort Maui at ... Forbes Five Star resort and Travel + Leisure’s No. 1 Hotel in Hawaii, has ...
(Date:9/4/2015)... ... 04, 2015 , ... The conference program for the upcoming ... 9-10, 2015 at the Diplomat Resort & Spa has been announced and is ... at the top of their field and will be presenting sessions such as ...
(Date:9/4/2015)... Washington, DC (PRWEB) , ... September 04, 2015 ... ... dollar-wise they all pale in comparison to settlements under the Stark physician self-referral ... an upcoming Sept. 17 webinar from Atlantic Information Services, Inc. (AIS), will ...
(Date:9/3/2015)... (PRWEB) , ... September 04, 2015 , ... AlignLife ... of September. , "There are so many children and adults who don't have ... says Dr. Sara Mahalko-Leonhardt. "We love holding our annual Coat Drive to help those ...
Breaking Medicine News(10 mins):Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:AlignLife is Helping to Keep the Community Warm This Winter 2
... Nov. 3 (HealthDay News) -- The rate of concussions among ... times higher than previously believed, and the issue needs to ... researchers warn. The study of 67 male ice-hockey players, ... during the 2009-2010 hockey season. During 52 games, 17 players ...
... TUESDAY, Nov. 2 (HealthDay News) -- One of the main ... symptoms in patients with early Alzheimer,s, although experts aren,t ruling ... the disease. The supplement, docosahexaenoic acid (DHA), is present ... it might play a role in treatment. But that ...
... report decreased pain and improved breathing following treatment of ... the therapy falls short of improving survival. Still, ... Cancer Center and presented today at the annual meeting ... BC, represents the first of its kind to document ...
... Birthdays Are Harder to Remember Than Others ( http://pss.sagepub.com/content/21/10/1525.abstract ... People may have a better memory for birthdays that ... birthdays tended to remember birthdays that were closer to ... their own birthday. In a separate experiment, after reading ...
... patients with the most common form of hepatitis C being ... hepatitis Cspecific protease inhibitor called telaprevir to the current standard ... cure) rate., The lead ... Ira M. Jacobson, chief of the Division of Gastroenterology and ...
... Serena Gordon HealthDay Reporter , TUESDAY, Nov. ... aren,t getting much-needed hospice care because the admission criteria ... cause of death in the U.S., and hospice care ... getting palliative [comfort] care is guidelines that try to ...
Cached Medicine News:Health News:Concussion Rate in Young Hockey Players Higher Than Thought 2Health News:Concussion Rate in Young Hockey Players Higher Than Thought 3Health News:Fish Oil Supplements May Not Slow Alzheimer's 2Health News:Fish Oil Supplements May Not Slow Alzheimer's 3Health News:Lombardi research: Robotic radiosurgery offers palliative care for hilar lung tumors 2Health News:New research from Psychological Science 2Health News:New research from Psychological Science 3Health News:New research from Psychological Science 4Health News:Hepatitis C study shows superior viral cure rate 2Health News:Study Casts Doubt on Hospice Admission Criteria for Patients With Dementia 2Health News:Study Casts Doubt on Hospice Admission Criteria for Patients With Dementia 3
(Date:9/4/2015)... India , September 4, 2015 ... 2015 Market Research Report is a professional and ... global Surgical Gown industry with a focus on ... take 2-3 working days once an order is ... market spread across 150 pages, analyzing and profiling ...
(Date:9/4/2015)... PLAINFIELD, N.J. , Sept. 4, 2015 /PRNewswire/ ... pleased to announce five recipients of its first-ever ... Realize Innovation, Vision and Empowerment), designed to aid ... Duchenne muscular dystrophy (DMD) community. The announcement is ... the international World Duchenne Awareness Day on Monday, ...
(Date:9/4/2015)... , Sept. 4, 2015  Allergan plc (NYSE: AGN ... Brent Saunders , CEO and President of Allergan, will provide ... Morgan Stanley Global Healthcare Conference 2015 in New ... The presentation will take place on ... the Grand Hyatt New York, 109 East 42nd Street, ...
Breaking Medicine Technology:Surgical Gown Market 2020 Forecasts With a Focus on China 2Surgical Gown Market 2020 Forecasts With a Focus on China 3Surgical Gown Market 2020 Forecasts With a Focus on China 4PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 3PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 4Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 2Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 3
... , ARDEE, Ireland, Dec. 11 As Warner ... its acquisition of the global branded prescription pharmaceuticals business ... 30, 2009 (the "PGP Acquisition"), constituted a change of ... "Marketing Agreement") between a P&G subsidiary acquired by Warner ...
... , LONDON and PHILADELPHIA, Dec. 11 ... breast cancer experienced a median survival of 14 months when ... (trastuzumab). The results of the Phase III study in HER2-positive ... San Antonio Breast Cancer Symposium, held in San Antonio, Texas ...
Cached Medicine Technology:Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes 2Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes 3Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes 4GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 2GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 3GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 4GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 5GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 6